Mycophenolate Mofetil Induced-Colitis: Is it More about Clinical Diagnosis?

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Yoghini Nagandran, Saikat Mandal, Ayuni Zahirah Zahar
{"title":"Mycophenolate Mofetil Induced-Colitis: Is it More about Clinical Diagnosis?","authors":"Yoghini Nagandran, Saikat Mandal, Ayuni Zahirah Zahar","doi":"10.2174/0115748863318109241104111738","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mycophenolate mofetil (MMF) is an immunosuppressant commonly used for treating autoimmune diseases.</p><p><strong>Case presentation: </strong>We report a diagnostically challenging case of MMF-induced colitis in a patient after 3 years of initiation of MMF therapy. A 76-year-old Caucasian female with a history of Chronic inflammatory demyelinating polyneuropathy receiving MMF presented to the hospital with a 7-weeks history of watery diarrhoea and crampy abdominal pains. Routine blood investigations, CMV-PCR, stool culture, viral PCR, Colonoscopy, and CT scan of the abdomen were broadly within normal limits. Histopathological changes were not significantly diagnostic apart from ischaemic-type changes. Finally, the reduction of the MMF dose caused the cessation of diarrhoea. Diagnosing MMF-induced colitis can be challenging, especially in patients on immunosuppressive medications. Further, long latency periods and non-specific colonoscopic and histopathologic changes add to the diagnostic dilemma.</p><p><strong>Conclusion: </strong>MMF-induced diarrhoea should be part of the clinician's differentials, and the decision to reduce the dose of MMF needs to be considered once infection and other causes have been ruled out.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863318109241104111738","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Mycophenolate mofetil (MMF) is an immunosuppressant commonly used for treating autoimmune diseases.

Case presentation: We report a diagnostically challenging case of MMF-induced colitis in a patient after 3 years of initiation of MMF therapy. A 76-year-old Caucasian female with a history of Chronic inflammatory demyelinating polyneuropathy receiving MMF presented to the hospital with a 7-weeks history of watery diarrhoea and crampy abdominal pains. Routine blood investigations, CMV-PCR, stool culture, viral PCR, Colonoscopy, and CT scan of the abdomen were broadly within normal limits. Histopathological changes were not significantly diagnostic apart from ischaemic-type changes. Finally, the reduction of the MMF dose caused the cessation of diarrhoea. Diagnosing MMF-induced colitis can be challenging, especially in patients on immunosuppressive medications. Further, long latency periods and non-specific colonoscopic and histopathologic changes add to the diagnostic dilemma.

Conclusion: MMF-induced diarrhoea should be part of the clinician's differentials, and the decision to reduce the dose of MMF needs to be considered once infection and other causes have been ruled out.

霉酚酸酯诱发性结肠炎:是否更注重临床诊断?
背景:霉酚酸酯(Mycophenolate mofetil, MMF)是一种常用的免疫抑制剂,用于治疗自身免疫性疾病。病例介绍:我们报告了一个MMF诱导结肠炎的诊断具有挑战性的病例,该患者在开始MMF治疗3年后。76岁白人女性,有慢性炎症性脱髓鞘多神经病变病史,接受MMF治疗,就诊时有7周水样腹泻和腹痛。血常规、CMV-PCR、粪便培养、病毒PCR、结肠镜检查、腹部CT扫描基本正常。除缺血型改变外,组织病理学改变无明显诊断意义。最后,MMF剂量的减少导致腹泻的停止。诊断mmf诱导的结肠炎可能具有挑战性,特别是在使用免疫抑制药物的患者中。此外,长潜伏期和非特异性结肠镜检查和组织病理学改变增加了诊断困境。结论:MMF引起的腹泻应是临床医生鉴别的一部分,一旦排除感染和其他原因,需要考虑减少MMF剂量的决定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信